ArticleCureus2026
Evaluation of Ki-67 Expression in Disordered Proliferative Endometrium, Endometrial Hyperplasia, and Endometrial Carcinoma.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEndometrial hyperplasia (EH) is characterized by elevated estrogen levels, which can lead to increased endometrial proliferation. Unopposed hyperestrogenism and elevated estrogen levels in conditions such as Lynch syndrome and estrogen-producing ovarian tumors can trigger endometrial proliferation and act as a predisposing factor for atypical endometrial hyperplasia (AEH) and endometrial carcinoma (EC). Recently, it has been considered that there is a progression from EH to endometrioid carcinoma. Disordered proliferative endometrium (DPE) is quantitatively similar to EH without atypia. The immunohistochemistry (IHC) marker Ki-67 reflects the degree of proliferation of malignant cells, as well as tumor invasion, metastasis, and prognosis in various malignancies. The aim of the study was to evaluate the expression of Ki-67 in DPE, EH without atypia, AEH, and EC, and to compare Ki-67 expression in low-grade and high-grade EC. METHODOLOGY: A hospital-based cross-sectional study was conducted in the Histopathology Section of the Department of Pathology using endometrial tissue samples obtained by endometrial curettage and hysterectomy from patients diagnosed with DPE, hyperplastic endometrium, and EC. For each case, an IHC study for the Ki-67 marker was performed.
resultsOut of 68 cases of endometrial lesions, 21 (30.88%) were DPE, 13 (19.12%) were EH with atypia, 16 (23.53%) were EH without atypia, and 18 (26.47%) were EC. The mean total Ki-67 positivity in EC was 60.16±24.26; in AEH, 22.56±4.98; in EH without atypia, 7.86±6.21; and in DPE, 13.23±15.68.
conclusionKi-67 can help differentiate DPE from EH without atypia and AEH when diagnostic difficulty arises on Hematoxylin and Eosin (H&E)-stained slides. Ki-67 expression was significantly higher in high-grade ECs than in low-grade ECs, suggesting a role for Ki-67 as a prognostic indicator and biomarker of aggressiveness. Hence, Ki-67 marker studies should be routinely performed in endometrial lesions such as DPE, EH without atypia, and AEH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.